The development of the neuromuscular synapse occurs via the interplay of signals between the innervating motor nerve and the muscle cells that leads to a progressive, localized specialization of the pre-and postsynaptic cells (Hall and Sanes, 1993) . A motoneuron-derived factor called agrin plays a key organizing role in this process and is required for the induction of many aspects of both pre-and postsynaptic differentiation (for review, see Bowe and Fallon, 1995; K leiman and Reichardt, 1996) . In particular, neural agrin induces the postsynaptic clustering of the acetylcholine receptor (Gautam et al., 1996) , as well as the accumulation at these clusters of other synaptic proteins such as rapsyn, dystroglycan, and utrophin (Wallace, 1989; C ampanelli et al., 1994; Gee et al., 1994; Bowe and Fallon, 1995) . Neural agrin seems to act via a receptor tyrosine kinase, MuSK, that is localized to the end-plate regions of skeletal muscle (Valenzuela et al., 1995) . Neural agrin induces a rapid tyrosine phosphorylation of that receptor , and in MuSK-deficient mice, there is a complete absence of postsynaptic differentiation, including clustering of acetylcholine receptor (AChR) beneath the nerve terminal .
Agrin also binds with relatively high affinity to ␣-dystroglycan (␣-DG) (Bowe et al., 1994; C ampanelli et al., 1994; Gee et al., 1994; Sugiyama et al., 1994) , a cell surface glycoprotein that is part of a transmembrane complex of dystrophin-associated proteins (for review, see Carbonetto and Lindenbaum, 1995) . ␣/␤-DG is concentrated at AChR clusters in vivo and in vitro, and antibodies to ␣-DG can disrupt agrin-induced AChR clustering (Campanelli et al., 1994; Gee et al., 1994 ; but see Sugiyama et al., 1994) . In addition, a minimal agrin fragment that lacks the ␣-DG-binding domain (Hopf and Hoch, 1996) is significantly less active in inducing AChR clustering and phosphorylation than are larger fragments that do bind ␣-DG (Gesemann et al., 1995 Meier et al., 1996) . These findings implicate ␣-DG in agrininduced AChR clustering; however the precise function of ␣-DG is currently unclear. ␣-DG could act as a coreceptor involved in presenting agrin to the receptor tyrosine kinase MuSK. Consistent with this idea, it has been proposed that a coreceptor is required for agrin-MuSK signaling because agrin does not bind or activate MuSK expressed in fibroblasts or myoblasts . Alternatively, ␣-DG may act downstream of agrinreceptor signaling by contributing to the growth and/or maintenance of AChR aggregates, or it may merely have a structural role in stabilizing the neuromuscular junction via interactions with the basal lamina.
To elucidate the role of ␣-DG in agrin-induced AChR clustering, we have generated antisense derivatives of the C2 mouse muscle cell line that have reduced ␣-DG. These lines show a dramatic reduction in the number of spontaneous and agrin-induced AChR clusters but little or no change in agrininduced MuSK and AChR ␤-subunit phosphorylation. Additionally, the activation of MuSK by agrin in wild-type C2 myotubes was not inhibited by treatments that block agrin -␣-DG binding or decreased using agrin fragments that do not bind ␣-DG. Together, these results suggest that ␣-DG is not required for agrin-MuSK signaling but that it may play a role in the subsequent formation of AChR clusters.
MATERIALS AND METHODS
Generation of ␣-DG antisense lines. An 1800 bp fragment of the mouse dystroglycan cDNA, extending from approximately Ϫ100 bp (5Ј to the translational start site) to the HindIII site situated at ϩ1725 bp, was removed by digestion of a mouse dystroglycan cDNA subclone in bluescript SK(Ϫ) (M. Lindenbaum and S. C arbonetto, unpublished observations) with NotI/HindIII. This NotI/HindIII cDNA fragment was then subcloned in the antisense orientation into the NotI/HindIII-digested expression vector pRC cytomegalovirus (Invitrogen, San Diego, CA) using standard subcloning techniques. Before transfection, the plasmid was linearized by digestion with BglII.
Stable transfections were performed on C2 myoblasts by the method of calcium phosphate coprecipitation. Briefly, C2 myoblasts plated on 10-cm dishes were incubated with fresh media for 3 hr, and the DNA /C aPO 4 coprecipitate was prepared using 5 g of linearized plasmid per plate. The coprecipitate was added to culture medium, and the cells were incubated for 16 hr. After incubation, the medium and precipitate were removed by aspiration, the cells were washed briefly with DPBS ϩ 0.5 mM EDTA to remove excess bound precipitate, and fresh medium was added. T wenty-four to thirty-six hours after the start of transfection, the medium was replaced with selection medium consisting of growth medium supplemented with 750 g /ml G418 (active concentration; Life Technologies, Gaithersburg, MD). Selection was performed for up to 10 d or until all the cells on an untransfected control plate were killed. At that point, drug-resistant C2 cell colonies could easily be seen on transfected plates. Colonies were then picked and expanded for f urther characterization. Once expanded, stable clones were maintained in 100 g /ml G418.
Culture of muscle cell lines. Mouse C2 muscle cells were cultured as described previously (Ferns et al., 1992) . Briefly, myoblasts were plated onto 100-mm tissue culture dishes and fed daily with DM EM with high glucose (DM EM-HI) supplemented with 20% fetal bovine serum, 5% chick embryo extract, and 100 U/ml penicillin -streptomycin (Life Technologies). After reaching confluence, cells were switched to f usion media (DM EM-HI supplemented with 1-5% horse serum and 100 g /ml L-glutamine) and allowed to differentiate into myotubes for 3-4 d. For experiments involving the ␣-DG antisense lines, all cells (C2, II F, and II E) were cultured in dishes coated with 0.1% gelatin.
Quantification of AChR clusters. For analysis of spontaneous and agrininduced clusters, wild-type C2 or ␣-DG antisense lines were grown within two compartments drawn with a wax pencil in Falcon 10-mm tissue culture dishes. After 3 d of differentiation in f usion media, myotube cultures were treated with recombinant agrin (C -Ag 4,8) at a range of concentrations for 16 hr, and the cultures were then fixed in 2% paraformaldehyde in PBS for 15 min. To visualize the AChR, we then incubated the myotubes in the compartments with rhodamine-conjugated ␣-bungarotoxin (1 g /ml; Molecular Probes, Eugene OR) for 20 min and coverslipped and viewed the myotubes with a Z eiss fluorescence microscope at a final magnification of 400ϫ. The number of AChR clusters above 2.5 m in diameter and the area of myotube segments (Gee et al., 1994) were determined for 10 -30 random fields for each compartment. The number of AChR clusters was expressed per myotube area to take into account any difference in cell density between the cultures. Statistical significance of differences in the responsiveness of C2, II F, and II E cells to agrin treatment was determined with an ANOVA and Fisher's test (using StatView).
Agrin f ragments and treatment. The C -Ag constructs used in these experiments have been described previously (Ferns et al., 1993) , and a truncated ϪG1 or N4 4,19 construct was generously provided by Werner Hoch (Hoch et al., 1994) . The 4,8 and 0,8 isoforms of the N4 fragment were generated by digesting the plasmid with KpnI and ligating in the corresponding fragment from C -Ag 4,8 or 0,8. The agrin fragments were expressed by transient transfection of C OS cells as described previously, and the concentration of the fragments in the conditioned media was determined by comparison with a standard of purified agrin on immunoblots (Ferns et al., 1993) .
For experiments assessing MuSK or AChR ␤-subunit tyrosine phosphorylation, agrin fragments were typically added to myotube cultures at 100 pM to 1 nM for 15-30 min. In competition experiments, neural agrin was added at 50 pM and muscle agrin at 5 nM. Anti-␣-dystroglycan antibody IIH6 was added at concentrations equivalent to those cited in Gee et al. (1994) .
E xtraction and isolation of MuSK and AChR . In assays for MuSK or AChR phosphorylation, myotube cultures were treated with agrin, rinsed, scraped off in C a-and Mg-free PBS containing 1 mM sodium vanadate, and pelleted. C ell pellets were then extracted with buffer containing 1% Triton X-100 and 25 mM Tris-glycine, pH 7.5, 150 mM NaC l, 5 mM EDTA, 1 mM sodium vanadate, 50 mM sodium fluoride, and the protease inhibitors 1 mM aprotinin, 1 mM leupeptin, 1 mM pepstatin A, 1 mM bisbenzamidine, 1 mM iodoacetamide, and 1 mM PMSF. After incubation on ice, the insoluble material was removed by centrif ugation at 16,000 ϫ g for 5 min at 4°C. The supernatant was retained, and the protein concentration of the extracts was determined.
To immunoprecipitate MuSK , we incubated the extracts at 4°C with an anti-MuSK peptide antibody for 1-2 hr and then with Protein G beads for an additional 1 hr. The beads were pelleted and washed four times in a 50 mM Tris buffer containing 0.5 M NaC l. The proteins isolated on the beads were then eluted directly in 30 l of SDS-PAGE sample buffer.
To isolate the AChR, we incubated the extracts with ␣-bungarotoxinconjugated beads for 1-2 hr and washed and eluted as above. Alternatively, to isolate selectively surface AChR, we added biotinylated ␣-bungarotoxin (Molecular Probes) to myotube cultures 1 hr before harvesting. C ells were then extracted as above and incubated with 100 l of streptavidin-conjugated sepharose beads (Molecular Probes) for 2 hr.
Western blot anal ysis. Samples were electrophoretically separated on 8% SDS-PAGE gels and transferred onto nitrocellulose membranes. For phosphotyrosine blots, the proteins were probed with a monoclonal anti-phosphotyrosine antibody (mAb 4G10; Upstate Biotechnology, Lake Placid, N Y) in buffer containing 5% BSA, 10 mM Tris-HC l, pH 7.4, 0.15 M NaC l, 0.5% N P40, and 0.1% T ween-20. The blots were then incubated with a horseradish peroxidase-conjugated anti-mouse Ig secondary antibody (Amersham, Arlington Heights IL) and bound antibody was visualized by chemiluminescence (ECL; Amersham). To probe for ␣-DG, we incubated the blots with mAb IIH6 in buffer with 5% dry milk and detected ␣-DG with an HRP-conjugated goat anti-mouse IgG-IgM secondary antibody. The immunoblots were reprobed for the AChR ␤-subunit with monoclonal antibody 124 or for MuSK with an anti-MuSK polyclonal antibody.
To quantif y levels of tyrosine phosphorylation, we performed densitometric analysis of the relevant bands using Sci-Scan 5000 Bioanalysis software (United States Biochemicals, C leveland, OH). To average several independent experiments, we expressed all values as a percentage of that for agrin-treated C2 cells at 60 min. We confirmed the accuracy of this analysis by running a dilution series of tyrosine-phosphorylated MuSK in which we found that the measured densities closely matched the expected values. In addition, we always performed the analysis on films with subsaturating exposure levels.
Antibodies. An anti-MuSK antisera was generated by injecting a 20 amino acid peptide corresponding to the C terminal of MuSK into each of two rabbits. After several boosts, the resulting antisera were tested for reaction against the immunizing peptides by ELISA. The IgG fraction was purified from the antisera of highest titer, and this antibody was found specifically to immunoprecipitate MuSK from C2 myotube extracts, as the immunoprecipitation could be competed by addition of excess peptide.
The mAb 124 specific to the ␤-subunit of the AChR was generously provided by Dr. J. Lindstrom (University of Pennsylvania), and the anti-␣-dystroglycan antibody IIH6 was generously provided by Dr. K . C ampbell (University of Iowa).
RESULTS

Acetylcholine receptor clustering is decreased in cell lines with reduced ␣-DG
We have tested whether ␣-DG is required for agrin-induced clustering by generating variants of the C2 mouse muscle cell line that express reduced levels of ␣-DG. Myoblasts were stably transfected with an antisense construct for ␣-DG and a neomycinresistance gene, and clones were selected for G418 resistance. Myotube cultures of each of the lines were then assayed for ␣-DG protein levels, and the results are shown in Figure 1 , A and B. The immunoblots shown were probed with anti-␣-DG antibody IIH6, but identical results were obtained with a polyclonal antibody to the core protein (M. Lindenbaum, F. Montanaro, and S. Carbonetto, unpublished observations). We found two lines that had significantly reduced levels of ␣-DG protein compared with that in wild-type C2 cells; these lines are IIF and IIE, which have ϳ40 and 10% of the C2 level, respectively ( Fig. 1 A) . Some other lines, such as 9B, 10C, and 11A, had levels of ␣-DG similar to that of wild-type C2 myotubes ( Fig. 1 B) and were used as controls. Further characterization of the cell lines indicated that the decrease in ␣-DG was specific, because several other proteins were still expressed at levels equivalent to those seen in the wild-type C2 myotubes, including the MuSK receptor tyrosine kinase ( Fig.  1 A) and ␣-sarcoglycan (Lindenbaum, Montanaro, and Carbonetto, unpublished observations). In addition, we found that surface levels of AChR were similar in all the lines (Fig. 1 A, B) and that all lines formed extensive myotubes, suggesting that the ␣-DG antisense lines reached a similar level of differentiation to that of wild-type C2 myotubes. In a separate study, we show that the decreased levels of ␣-DG in these lines reduce the amount of cell surface-associated laminin (Lindenbaum, Montanaro, and Carbonetto, unpublished observations).
To test whether ␣-DG is required for agrin-induced AChR clustering, we initially treated the different muscle cell lines with neural agrin at saturating concentrations (C-Ag 4,8 at 1 nM for 16 hr) and assayed AChR cluster numbers. We found that the two lines that have reduced levels of ␣-DG (IIF and IIE) also have significantly fewer agrin-induced AChR clusters compared with that in wild-type C2 cells (Fig. 1C) . In contrast, muscle lines expressing near wild-type levels of ␣-DG (9B, 10C, and 11A) showed normal levels of AChR clustering. The level of agrin-induced receptor clustering also appeared to correlate with the remaining level of ␣-DG in the two lines and did not correspond to AChR levels that were approximately equivalent in all lines. Thus, these findings suggest that ␣-DG is required for some phase of agrin-induced AChR clustering.
To define further the role of ␣-DG, we compared levels of AChR clustering in the IIF, IIE, and wild-type C2 lines in relation to agrin concentration. We found that the ␣-DG antisense lines have a reduced ability to form both spontaneous and agrin-induced AChR clusters compared with wild-type C2 myotubes. In control cultures (not treated with agrin), C2 myotubes had an average of 923 spontaneous AChR clusters/mm 2 , whereas IIE and IIF myotubes had only 187 and 34 clusters, respectively ( p Ͻ 0.0001, ANOVA and Fisher's test). Similarly, we found that the number of agrin-induced clusters is decreased in both IIF and IIE cells relative to that in C2 cells at all agrin concentrations tested (Fig. 2) . In particular, when agrin is applied in saturating and II E myotubes after overnight incubation with neural agrin, at concentrations ranging from 1 pM to 100 nM. The II F and II E myotubes with reduced ␣-DG show a significant decrease in the number of spontaneous and agrin-induced AChR clusters per myotube mm 2 compared with that in wild-type C2 cells ( p Ͻ 0.05 at all concentrations of agrin, by ANOVA and Fisher's test). All three muscle lines respond to agrin at similar concentrations; however the II F and II E cells form 2.7-and 4.8-fold fewer AChR clusters, respectively, at saturating agrin concentrations than do wild-type cells. Each value represents the mean Ϯ SD for two to five experiments.
concentrations (Ն1 nM), the peak cluster number is 2708, 1018, and 566 per mm 2 for C2, II F, and II E cells, respectively. After correcting for the differing levels of spontaneous clusters, we find that II F and II E cells form only 46 and 30% of the wild-type number of clusters, respectively ( p Ͻ 0.0001) (Fig. 2) . The ability of the antisense cells to cluster AChRs is thus approximately proportional to their expression level of ␣-DG, that is, 40% for IIF and 10% for II E cells.
Although spontaneous and peak cluster numbers differ between the three lines, the agrin dose -response curves for IIE and IIF are not shifted toward significantly higher effective concentrations relative to that for wild-type C2 myotubes (Fig. 2) . Indeed, the agrin concentration required to induce half-maximal AChR clustering in each line is 20 pM for C2 and 30 pM for the IIF and II E muscle lines. The ␣-DG antisense lines therefore respond to agrin at approximately equivalent concentrations to that of wild-type C2 cells but form fewer clusters. In addition, we find in preliminary experiments that these remaining clusters are the same size as those in wild-type C2 myotubes and that they have ␣-DG associated with them. Together, these results suggest that ␣-DG is required for agrin-induced AChR clustering but that it may not act in the initial, signaling phase of the pathway. In the following experiments, we test f urther whether this is the case.
Agrin-induced phosphorylation of MuSK and AChR ␤-subunit in C2 cell variants with reduced ␣-dystroglycan
Agrin has been shown to induce AChR clustering by signaling through the MuSK receptor tyrosine kinase Glass et al., 1996) and triggers a variety of intracellular events including tyrosine phosphorylation of the AChR ␤-subunit (Wallace et al., 1991; Meier et al., 1995; Ferns et al., 1996) . To test more directly whether ␣-DG might be involved in agrin signaling, we compared agrin-induced MuSK and AChR phosphorylation in C2 and the ␣-DG-deficient lines. The C2 and II E myotube cultures were treated with equal concentrations of recombinant neural agrin (C-Ag 4,8; 1 nM) (Ferns et al., 1993) , and immunoprecipitates of MuSK or AChR were electrophoresed and immunoblotted with an anti-phosphotyrosine antibody (mAb 4G10) (Fig. 3) . Reprobes of the immunoblots with antibodies to MuSK or to AChR subunits showed that equal levels of each were present in the C2 and II E samples (data not shown). A quantitative comparison of the levels of MuSK and AChR ␤-subunit phosphorylation in C2 and II E myotubes is shown in Figure 4 (n ϭ 3-7). For these experiments, densitometric analysis was always performed on exposures that were within the linear range of the film (see Materials and Methods). Comparing wild-type and II E myotubes treated with agrin for 15 min to 3 hr, we find that on average the level of agrin-induced phosphorylation of MuSK was comparable, with a reduction being evident in IIE myotubes only at 15 min ( p Ͻ 0.01, Student's t test; n ϭ 7) (Figs. 3A, 4A). Thereafter, there was a trend toward lower levels of MuSK phosphorylation in II E cells, but these differences were not statistically significant. Moreover, levels of MuSK phosphorylation were not decreased in the II F cell line at any time point (data not shown). In all cell lines, agrin-induced phosphorylation of MuSK began to decline after 1 hr and was only one-third of the peak level by 3 hr (Figs. 3A, 4A) . A similar, transient decrease in the level of MuSK phosphorylation in II E cells compared with that in wild-type C2 was also found using a lower agrin concentration of 200 pM (data not shown).
When we compared agrin-induced tyrosine phosphorylation of the AChR ␤-subunit, no significant difference was noted between C2 and IIE myotubes at any time point (Figs. 3B, 4B ; n ϭ 3). Thus, the transiently decreased level of MuSK phosphorylation in IIE myotubes compared with that in C2 myotubes was not reflected in the level of AChR tyrosine phosphorylation (Figs. 3B,  4 B) . Together, these findings show that although there is a transient reduction in agrin-induced MuSK phosphorylation in the IIE ␣-DG-deficient myotubes, this does not significantly affect downstream signaling events like phosphorylation of the AChR. It seems unlikely, therefore, that the approximately threefold decrease in the level of AChR clusters in IIE myotubes compared with that in wild-type myotubes is caused by a defect in initial agrin signaling.
Agrin-induced phosphorylation of MuSK does not require domains that bind ␣-DG or heparin
To investigate the possible role of ␣-DG further, we tested whether agrin-␣-DG binding is required for agrin signaling in wild-type C2 myotubes. Agrin has been shown previously to bind to ␣-DG through defined domains in the C terminal of agrin Hopf and Hoch, 1996) . We therefore tested whether ␣-DG acts as a coreceptor by deleting the primary ␣-DG-binding domains from agrin and then by assaying the ability of these agrin fragments to induce tyrosine phosphorylation of the MuSK receptor. We first compared agrin fragments that either contained or lacked the G1 domain that is primarily responsible for binding to ␣-DG (Fig. 5A) (Hopf and Hoch, 1996) . Neural agrin fragments that contained the G1 domain (C-Ag ϩ G1 4,8 or 0,8) induced a rapid and dramatic increase in MuSK tyrosine phosphorylation (Fig. 5B) . These agrin forms were active in inducing MuSK phosphorylation at concentrations of ϳ50 pM or greater. When we then examined agrin forms in which the G1 domain had been deleted (ϪG1 4,8 or 0,8), we found that they were similarly active in inducing MuSK phosphorylation. On average (n ϭ 4), there was no quantitative difference in the concentrations at which agrin forms plus and minus the first G1 domain were active. We conclude that the deletion of the G1 domain has no effect on the ability of agrin to induce MuSK phosphorylation (Fig. 5B) , and an agrin-␣-dystroglycan interaction via this domain is unlikely to be necessary in agrin signaling.
We also compared the activity of splice variants of agrin that contain or lack a 4 amino acid (aa) insert (Fig. 5A ) that has been shown to confer agrin binding to heparin (Campanelli et al., 1996; Gesemann et al., 1996; O'Toole et al., 1996) . Potentially this heparin-binding domain could mediate an interaction with ␣-DG or with some other proteoglycan coreceptor. We find that agrin isoforms that contain the 4 aa insert (C-Ag 4,8) induce, on average (n ϭ 3), a fivefold higher level of MuSK phosphorylation than do forms lacking this insert (C-Ag 0,8) (Fig. 5B) . Absence of the 4 aa insert also resulted in decreased activity in the truncated fragments that lack the G1 domain (ϪG1 4,8 compared with ϪG1 0,8). The presence of the 4 aa insert thus increases the ability of agrin to activate MuSK, possibly indicative of an interaction with a heparan sulfate proteoglycan in the agrin-signaling complex.
Competition of agrin binding to ␣-dystroglycan does not block agrin-induced phosphorylation of MuSK
Although agrin signaling does not seem to involve an interaction with ␣-DG via the G1 domain, agrin could interact weakly with ␣-DG via other binding domains. We therefore tested whether treatments that compete with neural agrin binding to ␣-DG might also inhibit agrin signaling. Muscle agrin has been shown to compete effectively with neural agrin binding to ␣-DG immobilized on nitrocellulose membranes and, in fact, has a 10-fold greater affinity for ␣-DG than does neural agrin (Sugiyama et al., 1994; Campanelli et al., 1996; Gesemann et al., 1996) . Myotubes treated with neural agrin in the presence of a 100-fold excess of muscle agrin (C-Ag 0,0 or C-Ag 4,0 at 5 nM) showed no decrease in agrin-induced phosphorylation of MuSK (Fig. 6 A) . Although this excess of muscle agrin may not fully saturate all ␣-DGbinding sites , we did not use higher amounts because muscle agrin can be active at very high concentrations (Ն50 nM) (Ferns et al., 1993) . The anti-␣-DG antibody IIH6 also blocks neural agrin binding to ␣-DG immobilized on immunoblots (Gee et al., 1994; Sugiyama et al., 1994) and expressed on cells (Campanelli et al., 1994) . Treatment with the IIH6 antibody failed to block agrin-induced phosphorylation of MuSK in myotubes treated with neural agrin either at 1 nM (Fig. 6 B) or 200 pM (data not shown). Thus, several treatments that specifically block the interaction of agrin with ␣-dystroglycan fail to inhibit agrininduced phosphorylation of MuSK.
Finally, heparin has also been shown to block the agrin-␣-DG interaction (Campanelli et al., 1994; Gee et al., 1994; Sugiyama et al., 1994; O'Toole et al., 1996) and to block agrin-induced AChR clustering (Wallace, 1990) . We find that agrin-induced phosphorylation of MuSK is blocked by soluble heparin in a dosedependent manner. Moreover, the inhibition with heparin was only observed for agrin forms that contain the 4 aa insert (Fig.  6C) . Thus, C-Ag 4,8-induced MuSK phosphorylation was significantly decreased by heparin at 100 g/ml, but C-Ag 0,8-induced phosphorylation was unaffected. Heparin presumably inhibits agrin activity, therefore, by binding only to the G2 domain of agrin forms that contain the 4 aa insert. It is unclear whether the blocking effect of heparin is caused by competition of a heparinlike interaction with ␣-DG or another unidentified proteoglycan, or merely by steric hindrance of binding to MuSK. 
DISCUSSION
We have investigated the potential role of ␣-dystroglycan in the formation of AChR clusters. We find that both spontaneous and agrin-induced AChR clustering are decreased in ␣-DG-deficient muscle cell lines compared with that in wild-type cells. This clustering defect seems to be attributable specifically to the decrease in ␣-DG because levels of other proteins like MuSK and the AChR were equivalent in all the muscle lines ( Fig. 1 A, B) and the defects in clustering correlated with the residual level of ␣-DG (Figs. 1C, 2 ). These observations suggest that ␣-DG is required for AChR clustering, and as a result we have examined whether ␣-DG acts in agrin signaling or elsewhere in the clustering pathway.
␣-DG is not a coreceptor for MuSK
Several findings suggest that a coreceptor, denoted MASC (for myotube-associated specificity component), is necessary for the activation of the MuSK receptor tyrosine kinase by agrin . ␣-Dystroglycan is an obvious candidate for MASC, because ␣-DG has been shown to bind agrin (Campanelli et al., 1994) and to cocluster together with the AChR (C ampanelli et al., 1994; Gee et al., 1994; Sugiyama et al., 1994; Cohen et al., 1995) . Several of our findings suggest, however, that ␣-DG is not required for agrin-MuSK signaling. First, we found that agrin acted at equivalent concentrations in wild-type and ␣-DGdeficient lines, indicating that there is not a shift in the doseresponse curve for agrin in the ␣-DG-deficient lines. Secondly, we found that agrin-MuSK signaling was not substantially inhibited in the ␣-DG-deficient lines compared with that in wild-type cells. Although agrin-induced phosphorylation of MuSK was slightly reduced in IIE compared with that in wild-type C2 cells (but only significantly so at 15 min), the downstream tyrosine phosphorylation of the AChR ␤-subunit was equivalent at all time points assayed. The levels of MuSK and AChR ␤-subunit phosphorylation are therefore equalized well in advance of AChR clustering, which was assayed in these experiments at 18 hr. Thus, there does not seem to be a major or long-lasting defect in agrin signaling in the ␣-DG-deficient lines that might account for their dramatically decreased level of AChR clustering. We cannot entirely discount a signaling role for ␣-DG, however, because the residual ␣-DG in the antisense lines may be sufficient for function as a coreceptor.
The findings from several, independent experiments on wildtype C2 cells provide further evidence against a signaling role for ␣-DG. Foremost, we find that the domain of agrin that binds ␣-DG is not required for agrin-MuSK signaling. When we deleted the primary ␣-DG-binding domain in agrin (laminin G1 domain; Figure 5 . Agrin-induced phosphorylation of MuSK correlates with heparin but not ␣-DG binding. A, Schematic depicting the agrin constructs used to test whether agrin-induced phosphorylation of MuSK is dependent on the first G domain that binds ␣-DG with high affinity (horizontal solid line) or on the 4 amino acid-splicing insert that confers binding to heparin (horizontal solid line). The region responsible for clustering activity (horizontal solid line) and its dependence on the splicing inserts at sites x, y, and z are also shown. Dashed lines denote regions that make minor contributions to ␣-DG binding or to AChR clustering activity. Neural agrin forms contain the 4 and 8 amino acid inserts (denoted 4,8), whereas muscle agrin forms lack both these inserts (0,0). The domains of agrin are represented as follows: ST, serine/threonine-rich domain; E1-E4, EGF-like domains; and G1-G3, laminin globular domains. B, Phosphotyrosine immunoblot of MuSK isolated from C2 myotubes that were incubated with the indicated agrin construct for 15 min at 1 nM. The presence or absence of the first G1 domain has no effect on the ability of agrin to induce MuSK phosphorylation (compare the ϩG1 and ϪG1 lanes for each isoform). In contrast, the 4 amino acid insert does affect the level of MuSK phosphorylation (compare the 4,8 vs 0,8 lanes) but is not absolutely required. The letter c indicates the control with no agrin treatment, and 0,0 represents the muscle isoform. Molecular mass markers are indicated to the lef t. Hopf and Hoch, 1996) , we found absolutely no effect on the ability of agrin to induce tyrosine phosphorylation of MuSK (Fig.  5 ). This result is consistent with previous studies that have shown that the ability of agrin fragments to induce AChR clustering is not significantly affected by the presence of the first G1 domain (Hoch et al., 1994; Gesemann et al., 1995) .
In addition, we found that treatments that are known to block agrin-␣-dystroglycan binding also failed to inhibit agrin signaling via MuSK. For example, muscle agrin binds ␣-DG with 10-fold greater affinity than does neural agrin (Sugiyama et al., 1994; Gesemann et al., 1996) ; yet excess muscle agrin failed to inhibit neural agrin-induced phosphorylation of MuSK, consistent with earlier work showing that it does not block AChR clustering . Similarly, inhibition of agrin binding to ␣-DG with the anti-␣-DG antibody IIH6 (Campanelli et al., 1994; Gee et al., 1994; Sugiyama et al., 1994) had no effect on the activation of MuSK by agrin (Fig. 6 B) . The reported disruption of agrin-induced AChR clustering by this anti-␣-DG antibody (Campanelli et al., 1994; Gee et al., 1994) thus does not stem from a block of signaling (see below). These several independent lines of evidence argue strongly against ␣-DG acting as a coreceptor that is required for agrin-MuSK signaling.
Although specific inhibitors of agrin-␣-DG binding did not affect signaling, we did observe a block of MuSK phosphorylation using heparin. Heparin has been shown previously to inhibit nerve-and agrin-induced receptor clustering (Hirano and Kidokoro, 1989; Wallace, 1990) and to block the agrin-␣-DG interaction (Campanelli et al., 1994; Gee et al., 1994; Sugiyama et al., 1994; O'Toole et al., 1996) . We found that heparin effectively inhibits agrin-induced phosphorylation of MuSK, but only for agrin forms containing the 4 amino acid splice insert in the second G domain (Fig. 6C ). Because this 4 aa insert has been shown to confer heparin binding (Campanelli et al., 1996; Gesemann et al., 1996; O'Toole et al., 1996) , this indicates that heparin is acting by binding directly to agrin rather than to some cell surface component. It is unclear whether this reflects the block of the interaction of agrin with a proteoglycan or is merely attributable to steric hindrance of agrin binding to MuSK. We also found that agrin isoforms that contained the 4 aa insert induced a fivefold higher level of MuSK phosphorylation than did forms lacking this insert (Figs. 5B, 6C) , consistent with earlier studies assaying AChR-clustering activity of different agrin isoforms (Ferns et al., 1993) . These results allow the possibility that agrin binding to a proteoglycan plays a small role in agrin signaling, but one that is not absolutely required. The blocking experiments, discussed above, make it unlikely that ␣-DG is involved in this putative heparin-binding interaction with agrin. Moreover, there is currently some debate as to whether ␣-DG is in fact a proteoglycan, and some results suggest it may instead have a mucin-like structure (Smalheiser and Kim, 1995; Chiba et al., 1997) .
The role of ␣-DG in AChR clustering
We have found that muscle lines with reduced ␣-DG exhibit seemingly normal signaling through the MuSK receptor and yet form significantly fewer AChR clusters than do wild-type cells, suggesting that ␣-DG is required at some other stage of the clustering pathway. Given that the activation of the MuSK receptor by agrin is thought to be the initial event and occurs very rapidly, it seems most likely that ␣-DG acts downstream in the pathway, such as in the consolidation of microclusters or in the growth and maintenance of AChR aggregates. Consistent with this notion, previous studies have shown that treatment with an anti-␣-DG antibody disrupts both spontaneous and agrin-induced AChR clustering (Campanelli et al., 1994; Gee et al., 1994; Cohen et al., 1995 ; but see Sugiyama et al., 1994) . In particular, Campanelli et al. (1994) reported that the anti-␣-DG antibodies appeared to block the consolidation of microclusters into larger aggregates, suggesting that ␣-DG might act at a stage of clustering subsequent to initial agrin signaling. In addition, heparin has recently been shown to partially inhibit some downstream step in Model showing where ␣-DG might act in agrin-induced AChR clustering. Our findings suggest that ␣-DG probably does not act as a coreceptor involved in initial agrin signaling via the MuSK receptor complex (1). Rather, ␣-DG might f unction downstream of MuSK activation, in the initial formation of AChR aggregates (2) or in the consolidation and maintenance of clusters (3). Consistent with this idea, ␣-DG becomes coclustered with MuSK and the AChR and could be required for the f urther development of this postsynaptic scaffold. For example, ␣-DG might form part of the scaffold that immobilizes and stabilizes AChR aggregates, possibly via its links to the extracellular matrix and the cytoskeleton (3). Rap, Rapsyn; ␣, ␤, ␣-and ␤-dystroglycan; and P, tyrosine phosphorylation.
